Year Founded
2021
Ownership
Private
Employees
~20
Therapeutic Areas
PsychiatryNeurology
Stage
Preclinical
Modalities
Small moleculeOther

Sensorium Therapeutics General Information

Developing SENS-01 for anxiety and depression, showing promise in pre-clinical studies with IND-enabling studies planned for 2023 and clinical entry expected by early 2024

Contact Information

Website
Primary Industry
[ "Biotech" ]
Corporate Office
Boston, Massachusetts
United States

Drug Pipeline

SENS-01
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Sensorium Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Sensorium Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Sensorium Therapeutics's complete valuation and funding history, request access »

Sensorium Therapeutics Investors

Raised $30 million in Series A funding (announced November 8, 2022)[7]
Investor Type: Venture Capital
Holding: Minority